Leuplin leuprorelin acetate: Phase III started

Takeda began an open-label, Japanese Phase III trial to evaluate a 6-month formulation of Leuplin in about 160 prostate cancer patients. Leuplin is approved to treat prostate cancer and premenopausal ...